Screening for breast cancer brain metastases – Authors' reply

We thank Jonathan Knisely for his response to our Article on the PERMEATE study of brain metastases in breast cancer. We agree that current guidelines need to be updated to recommend regular screening for brain metastases, especially for asymptomatic patients with HER2-positive or triple-negative metastatic breast cancer. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trialTo our knowledge, this is the first prospective study showing the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive breast cancer and brain metastases, especially in radiotherapy-naive population. This combination deserves further validation in a randomised, controlled trial. Full-Text PDF Screening for breast cancer brain metastasesThe results of the phase 2 trial of pyrotinib plus capecitabine for patients with brain metastases arising from HER2-positive breast cancer are welcome news—breast cancer brain metastases are both common and feared.1 New CNS-active systemic therapies will benefit many patients. Full-Text PDF